The drugmaker has cut costs already and has no coming product approvals or research that could offer a quick lift.
Related Posts
Teva Soars, Sanofi Gains on Strong Trial Results for IBD Treatment
Duvakitug was generally well tolerated across patient groups and showed similar rates of treatment-emergent adverse events, according to the companies.
Winemaker Duckhorn Agrees to Be Taken Private in $1.95 Billion Deal
Duckhorn Portfolio has agreed to be taken private by Butterfly Equity in an all-cash deal that values the winemaker at $1.95 billion.
U.K. Regulator to Scrutinize Hewlett Packard Enterprise-Juniper Networks Merger
U.K. regulators will probe the potential merger, in which the Texas-based IT firm, known as HPE, aims to buy the California-based artificial intelligence company in […]